About 9.4M results
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity …
Novo Nordisk’s obesity newcomer monlunabant heads into …
Novo Nordisk Slips On Phase 2a Clinical Trial Result With Monlunabant
Novo Nordisk Stock Declines After Headline Results From Mid …
Novo Nordisk shares drop nearly 5% on disappointing obesity pill …
Novo Shares Fall After Mixed Safety Data on New Weight-Loss Drug
Novo’s obesity drug linked to ‘neuropsychiatric side effects’
- Some results have been removed